In next-gen IO race in NSCLC, BioNTech/BMS and Pfizer are divided on overall survival approach

In the race to forge the next Keytruda from PD-(L)1xVEGF bispecific antibodies, Pfizer and the BioNTech-Bristol Myers Squibb alliance are split on how to position overall survival—the gold-standard oncology endpoint—in their first-line non-small cell lung cancer clinical trials.